Tejada-Simons, MariVi

Small Rho GTPases, a Potential Therapeutic Target for Fragile X Syndrome

FRAXA Research Foundation 2006-2010 Grants • 2011 Grants • 2012 Grants • 2013 Grants • Disease Mechanisms • Research Grant Results • Tejada-Simons, MariVi • Treatment Targets • University of Houston January 30, 2013May 18, 2020glutamate, lovastatin, mGluR, mGluR5, NIH, Rac1

With $384,345 in grants from FRAXA Research Foundation, Dr. MariVi Tejada from the University of Houston focused on a particularly promising point of intervention in pathways of brain receptors, and tested several potential therapeutic compounds in an attempt to rescue function in the mouse model of Fragile X.